In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
775: New Guidelines Recommend Earlier Breast Cancer Screening
773: New Rule Sets Stage For Electric Grid Update | Harnessing Nanoparticles For Vaccines
772: How Climate Change Is Changing Sports
771: Why Is Tinnitus So Hard To Understand And Treat?
770: Finding Purpose In A ‘Wild Life’
769: Archeopteryx Specimen Unveiled | Trees And Shrubs Burying Great Plains' Prairies
768: JWST Detects An Atmosphere Around A Rocky Exoplanet | Boeing Plans To Fly Humans To The ISS Next Week
767: Challenging The Gender Gap In Sports Science
766: What Martian Geology Can Teach Us About Earth
765: How Louisiana Is Coping With Flooding In Cemeteries
764: Inside Iowa State’s Herbarium | Science-Inspired Art From ‘Universe of Art’ Listeners
763: Science From Iowa’s Prairies | Planning To Go See Cicadas? Here’s What To Know
762: Maybe Bonobos Aren't Gentler Than Chimps | Art Meets Ecology In A Mile-Long Poem
761: When Products Collect Data From Your Brain, Where Does It Go?
760: Visualizing A Black Hole’s Flares In 3D
759: The 4,000-Year History of Humans and Silk
758: Flint’s Water Crisis, 10 Years Later | Underwater Cables Could Help Detect Tsunamis
757: Fighting Banana Blight | Do Birds Sing In Their Dreams?
756: Why Is Solving The Plastic Problem So Hard?
755: What Worsening Floods Mean For Superfund Sites
Create your
podcast in
minutes
It is Free
The Modern West
Voices of Misery Podcast
House of Whimsical Terror
Dairyland Frights
Stuff You Should Know
Timcast IRL